Innovating for screening
Screening to prevent, treat and cure
Sample analysis
Data processing
Assistance in the
interpretation of data
Automate biological screening, improve its efficiency, reduce mortality, while reducing the cost of analysis
Integrative and scalable biomedical analysis solutions that we adapt to your needs
High analytical sensitivity
Low costs of analysis
Robustness and traceability
Latest news and events
See the latest news
NeoSickle makes a successful transition to the new IVD regulations
16/10/23
Biomaneo's first IVDR CE-certified product
Detection of a new case of Hb Wanjiang.
11/07/23
This discovery was the subject of a new publication
Biomaneo becomes a subsidiary of Shimadzu Corporation
09/06/23
Biomaneo becomes a wholly-owned subsidiary of Shimadzu Corporation (Kyoto, Japan)
4th Global Congress on Sickle Cell Disease
14/06/22
Join Biomaneo & Shimadzu at the 4th Global Congress on Sickle Cell Disease taking place in Paris from June 16-18.
Biomaneo obtains ISO 13485:2016 certification and strengthens its quality team
31/08/21
A key step for the marketing of its In Vitro Diagnostic Devices (IVDD) and in the transition to the new 2017/746 regulation.
New NeoSickle installation
26/08/21
With this second installation, 80% of French samples are now analysed using the NeoSickle solution.
Biomaneo puts the spotlight on the training of young people...
23/10/20
By welcoming three new employees to its teams
Biomaneo obtains the "Label Initiative Remarquable"
21/09/20
We are pleased to announce that we have just joined the 1st community of impact entrepreneurs in France...
A new shareholder into our business
20/12/19
In Dijon, Biomaneo is collecting additional financial resources from BFC Croissance & Innovation to continue the development of screening...
